Clinical features, imaging findings, and treatment outcomes of optic neuritis associated with anti-CRMP5 antibodies: a systematic review.

J NeuroimmunolJun 27, 2026 (epub)

Rafael Martins Themoteo, Yang Han Yu, Joana Laura Aihara Barbosa et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed 32 patients with optic neuritis associated with anti-CRMP5 antibodies. The study found that 87.1% had bilateral optic neuritis, with 64% experiencing visual acuity worse than 20/200. A significant 90.6% had an associated malignancy, primarily small-cell lung carcinoma. Overall mortality was 32.1% at a median follow-up of 9.5 months.

Key findings

  • 87.1% of patients had clinically symptomatic bilateral optic neuritis.
  • Overall mortality was 32.1% at a median follow-up of 9.5 months.
  • 90.6% of cases had an associated malignancy, mostly small-cell lung carcinoma.
  • Absence of tumor response to treatment was linked to 88.9% mortality.

Why it matters

Understanding the clinical features and outcomes of optic neuritis related to anti-CRMP5 antibodies is crucial for timely diagnosis and management, especially given the high association with malignancies and significant mortality rates.

Source

Published in J Neuroimmunol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.